comparemela.com

Latest Breaking News On - Alexandra harrison - Page 2 : comparemela.com

RE+NorthEast 2023-Clean Energy Forum in Boston, MA

RE+NorthEast 2023 welcomed a large group of keynote speakers and policymakers who shared their expertise and opinion during structured group discussions and networking.

New yorkUnited statesJohn williamsDeb peck kelleherAlexandra harrisonAdam sokolskiAbigail ross hopperRobert nicholsonDays forumAlliance for clean energyRegulatory affairsWilliam forestry associatesEvent association managementExpertise that promotes green energy for livingGenie solar energyPv panel recycling

PHARNEXT: Pharnext refocuses its clinical trial programs on PXT3003, its most promising drug candidate, to optimize financial resources allocation

PARIS, France, February 14th, 2023, 08:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative

United statesFrance generalDennis riedlMary jane elliottFabreguettes leibDeborah schwartzHugo brugiAlexandra harrisonSukaina virjiFinancial press relationsRelations internationalCompany board of directorsConsilium strategic communicationsAmyotrophic lateral sclerosisEuronext growthNeuroscience res

PHARNEXT: Pharnext unveils the latest progress of the PREMIER trial, pivotal Phase III clinical trial of PXT3003 in Charcot-Marie-Tooth disease type 1A

PARIS, France, February 2nd, 2023, 08:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative

United statesFrance generalBaden wübergDeborah schwarzMary jane elliottFabreguettes leibAlexandra harrisonSukaina virjiSchwierige zeitenFinancial press relationsRelations internationalEuronext growth stock exchangeClinical development programConsilium strategic communicationsOverall neuropathy limitations scaleOpen label extension

PHARNEXT: Pharnext announces successful completion of manufacturing transfer and scale-up of PXT3003 in the United States

Pharnext announces successful completion of manufacturing transfer and scale - up of PXT3003 in the United States PARIS, France, January 26th, 2023, 08:30 am CET - Pharnext SA (FR001400BV89 - ALPHA)

New yorkUnited statesFrance generalUnither colomiersUnither rochesterMary jane elliottFabreguettes leibAlexandra harrisonSukaina virjiRaj thotaEuronext growth stock exchangeMedia relations internationalConsilium strategic communicationsChief manufacturing officerPresse financi

PHARNEXT: Pharnext supports and participates in the 21st King s College Symposium on Neuromuscular Diseases in London

Pharnext supports and participates in the 21st King's College Symposium on Neuromuscular Disease s in London PARIS, France, January 25th, 2023, 08:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the

United statesFrance generalUnited kingdomCity ofDeborah schwarzRoger rolphMary jane elliottFabreguettes leibAlexandra harrisonSukaina virjiFinancial press relationsKing college symposium on neuromuscular diseasesNeuromuscular disease symposium at king collegeFetal medicine research instituteEuronext growth stock exchangeKing college symposium on neuromuscular disease

vimarsana © 2020. All Rights Reserved.